Drugs and devices in the pipeline from Bayer Healthcare, AVEO Oncology, Astellas Pharma Inc., Trimel Pharmaceuticals Corp., OncoGenex Pharmaceuticals, Inc., Nymox Pharmaceutical Corp., Spectrum Pharmaceuticals, and Tengion, Inc.
Modern Medicine Now
The tax laws have changed once again. Find out how they're going to affect you.
To optimize outcomes for patients with advanced renal cell carcinoma, multimodal therapy is often required.
The incidence of secondary malignancies following prostate cancer therapy is similarly uncommon whether the treatment is surgery, brachytherapy, or external beam therapy.
Recent analyses of urodynamic testing data indicate that both autologous fascial pubovaginal sling and synthetic midurethral sling procedures decrease maximum flow rate and increase bladder outlet resistance, but the pubovaginal sling was found to create more bladder outlet resistance.
Advanced age does not influence postoperative continence or cancer-specific survival after radical prostatectomy, according to a recent study.
For women with uncomplicated, stress-predominant incontinence, urodynamic testing adds considerable expense without improving surgical outcomes, a recent trial shows.
Urologists share how confident they feel about active surveillance for low-risk prostate cancer.
Preoperative urodynamic testing in women undergoing surgery for uncomplicated, stress-predominant urinary incontinence commonly results in a change in clinical diagnosis.
OnabotulinumtoxinA (Botox) has earned FDA approval for the treatment of overactive bladder in adults who cannot use or don't adequately respond to anticholinergic drugs, and its potential uses in urology may not end there.